Treating pulmonary hypertension in the elderly

References

• Lang IM, Benza R. Pulmonary hypertension: chapters of innovation and tribulation. Eur Heart J. 2012;33(8):961–968.
   PubMed Web of Science ®Google Scholar
• Humbert M, Sitbon O, Chaouat A, et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med. 2006;173(9):1023–1030.
   PubMed Web of Science ®Google Scholar
• Galie N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: the joint task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): endorsed by: association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Respir J. 2015;46(4):903–975.
   PubMed Web of Science ®Google Scholar
• Galie N, McLaughlin VV, Rubin LJ, et al. An overview of the 6th World symposium on pulmonary hypertension. Eur Respir J. 2019;53(1):1.
   Web of Science ®Google Scholar
• Simonneau G, Montani D, Celermajer DS, et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J. 2019;53(1):1..
   Web of Science ®Google Scholar
• Humbert M. Pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: pathophysiology. Eur Respir Rev. 2010;19(115):59–63.
   PubMedGoogle Scholar
• Lang IM, Klepetko W. Update on chronic thromboembolic pulmonary hypertension, a frequently undiagnosed condition. Rev Esp Cardiol. 2009;62(2):120–125.
   PubMed Web of Science ®Google Scholar
• Hoeper MM, Huscher D, Ghofrani HA, et al., Elderly patients diagnosed with idiopathic pulmonary arterial hypertension: results from the COMPERA registry. Int J Cardiol. 168(2): 871–880. 2013.
   PubMed Web of Science ®Google Scholar
• Ling Y, Johnson MK, Kiely DG, et al., Changing demographics, epidemiology, and survival of incident pulmonary arterial hypertension: results from the pulmonary hypertension registry of the United Kingdom and Ireland. Am J Respir Crit Care Med. 186(8): 790–796. 2012.
   PubMed Web of Science ®Google Scholar
• Badesch DB, Raskob GE, Elliott CG, et al. Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry. Chest. 2010;137(2):376–387.
   PubMed Web of Science ®Google Scholar
• Frost AE, Badesch DB, Barst RJ, et al. The changing picture of patients with pulmonary arterial hypertension in the United States: how REVEAL differs from historic and non-US contemporary registries. Chest. 2011;139(1):128–137.
   PubMed Web of Science ®Google Scholar
• Radegran G, Kjellstrom B, Ekmehag B, et al. Characteristics and survival of adult Swedish PAH and CTEPH patients 2000–2014. Scand Cardiovasc J. 2016;50(4):243–250.
   PubMed Web of Science ®Google Scholar
• Skride A, Sablinskis K, Lejnieks A, et al. Characteristics and survival data from Latvian pulmonary hypertension registry: comparison of prospective pulmonary hypertension registries in Europe. Pulm Circ. 2018;8(3):2045894018780521.
   Web of Science ®Google Scholar
• Jansa P, Jarkovsky J, Al-Hiti H, et al. Epidemiology and long-term survival of pulmonary arterial hypertension in the Czech Republic: a retrospective analysis of a nationwide registry. BMC Pulm Med. 2014;14(1):45.
   PubMedGoogle Scholar
• Thenappan T, Shah SJ, Rich S, et al. Survival in pulmonary arterial hypertension: a reappraisal of the NIH risk stratification equation. Eur Respir J. 2010;35(5):1079–1087.
   PubMed Web of Science ®Google Scholar
• Rich S, Dantzker DR, Ayres SM, et al. Primary pulmonary hypertension. A national prospective study. Ann Intern Med. 1987;107(2):216–223.
   PubMed Web of Science ®Google Scholar
• Hoeper MM, Huscher D, Pittrow D. Incidence and prevalence of pulmonary arterial hypertension in Germany. Int J Cardiol. 2016;203:612–613.
   PubMed Web of Science ®Google Scholar
• Benza RL, Miller DP, Barst RJ, et al. An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry. Chest. 2012;142(2):448–456.
   PubMed Web of Science ®Google Scholar
• Benza RL, Miller DP, Gomberg-Maitland M, et al. Predicting survival in pulmonary arterial hypertension: insights from the registry to evaluate early and long-term pulmonary arterial hypertension disease management (REVEAL). Circulation. 2010;122(2):164–172.
   PubMed Web of Science ®Google Scholar
• Hjalmarsson C, Radegran G, Kylhammar D, et al., Impact of age and comorbidity on risk stratification in idiopathic pulmonary arterial hypertension. Eur Respir J. 51(5): 5. 2018.
   Web of Science ®Google Scholar
• Enright PL. The six-minute walk test. Respir Care. 2003;48(8):783–785.
   PubMedGoogle Scholar
• Ginoux M, Turquier S, Chebib N, et al., Impact of comorbidities and delay in diagnosis in elderly patients with pulmonary hypertension. ERJ Open Res. 4(4): 4. 2018.
   Google Scholar
• Pugh ME, Sivarajan L, Wang L, et al. Causes of pulmonary hypertension in the elderly. Chest. 2014;146(1):159–166.
   PubMed Web of Science ®Google Scholar
• Hoeper MM, Barbera JA, Channick RN, et al. Diagnosis, assessment, and treatment of non-pulmonary arterial hypertension pulmonary hypertension. J Am Coll Cardiol. 2009;54(1 Suppl):S85–96.
   PubMed Web of Science ®Google Scholar
• Berra G, Noble S, Soccal PM, et al. Pulmonary hypertension in the elderly: a different disease? Breathe (Sheff). 2016;12(1):43–49.
   PubMedGoogle Scholar
• Fayyaz AU, Edwards WD, Maleszewski JJ, et al. Global pulmonary vascular remodeling in pulmonary hypertension associated with heart failure and preserved or reduced ejection fraction. Circulation. 2018;137(17):1796–1810.
   PubMed Web of Science ®Google Scholar
• Gerges C, Gerges M, Skoro-Sajer N, et al. Hemodynamic thresholds for precapillary pulmonary hypertension. Chest. 2016;149(4):1061–1073.
   PubMed Web of Science ®Google Scholar
• Konstantinides SV, Meyer G, Becattini C, et al. ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J. 2020 Jan;41(4):543-603.
   Web of Science ®Google Scholar
• Galie N, Barbera JA, Frost AE, et al. Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension. N Engl J Med. 2015;373(9):834–844.
   PubMed Web of Science ®Google Scholar
• Pulido T, Adzerikho I, Channick RN, et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med. 2013;369(9):809–818.
   PubMed Web of Science ®Google Scholar
• Sitbon O, Channick R, Chin KM, et al. Selexipag for the treatment of pulmonary arterial hypertension. N Engl J Med. 2015;373(26):2522–2533.
   PubMed Web of Science ®Google Scholar
• Sitbon O, Humbert M, Jais X, et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation. 2005;111(23):3105–3111.
   PubMed Web of Science ®Google Scholar
• Opitz CF, Hoeper MM, Gibbs JS, et al., Pre-capillary, combined, and post-capillary pulmonary hypertension: a pathophysiological continuum. J Am Coll Cardiol. 68(4): 368–378. 2016.
   PubMed Web of Science ®Google Scholar
• Ende-Verhaar YM, Cannegieter SC, Vonk Noordegraaf A, et al. Incidence of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism: a contemporary view of the published literature. Eur Respir J. 2017;49:2.
   Web of Science ®Google Scholar
• Bunclark K, Newnham M, Chiu YD, et al. A multicenter study of anticoagulation in operable chronic thromboembolic pulmonary hypertension. J Thromb Haemost. 2020 Jan;18(1):114-122.
   Web of Science ®Google Scholar
• Ghofrani HA, D’Armini AM, Grimminger F, et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N Engl J Med. 2013;369(4):319–329.
   PubMed Web of Science ®Google Scholar
• Sadushi-Kolici R, Jansa P, Kopec G, et al., Subcutaneous treprostinil for the treatment of severe non-operable chronic thromboembolic pulmonary hypertension (CTREPH): a double-blind, phase 3, randomised controlled trial. Lancet Respir Med. 7(3): 239–248. 2019.
   PubMed Web of Science ®Google Scholar
• Mizoguchi H, Ogawa A, Munemasa M, et al. Refined balloon pulmonary angioplasty for inoperable patients with chronic thromboembolic pulmonary hypertension. Circ Cardiovasc Interventions. 2012;5(6):748–755.
   PubMed Web of Science ®Google Scholar
• Brenot P, Jais X, Taniguchi Y, et al. French experience of balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension. Eur Respir J. 2019;53(5):1802095.
   PubMed Web of Science ®Google Scholar
• McLaughlin VV, Vachiery JL, Oudiz RJ, et al. Patients with pulmonary arterial hypertension with and without cardiovascular risk factors: results from the AMBITION trial. J Heart Lung Transplant. 2019;38(12):1286–1295.
   PubMed Web of Science ®Google Scholar
• Kylhammar D, Kjellstrom B, Hjalmarsson C, et al., A comprehensive risk stratification at early follow-up determines prognosis in pulmonary arterial hypertension. Eur Heart J. 39(47): 4175–4181. 2018.
   PubMed Web of Science ®Google Scholar
• Boucly A, Weatherald J, Savale L, et al., Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension. Eur Respir J. 50(2): 2. 2017.
   Web of Science ®Google Scholar
• Hoeper MM, Pittrow D, Opitz C, et al. Risk assessment in pulmonary arterial hypertension. Eur Respir J. 2018;51:3.
   Google Scholar
• Hoeper MM, Kramer T, Pan Z, et al., Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model. Eur Respir J. 50(2): 2. 2017.
   Web of Science ®Google Scholar